MedAvante

What MedAvante does

MedAvante, founded in 2002 and headquartered in Hackensack, New Jersey, is a clinical trial technology and services company focused on technology-enabled signal detection and endpoint solutions for drug development. The company serves large pharmaceutical sponsors, biotechnology firms, and contract research organizations (CROs) across all phases of clinical trials, deploying its platform across more than 100 countries with translations in over 100 languages. MedAvante has supported more than 30,000 clinical trials and has contributed to 700+ FDA and EMA new drug approvals, including 70% of FDA and EMA approvals since 2015.

The company's product portfolio spans eCOA (Electronic Clinical Outcome Assessment), cardiac safety solutions including ECG and arrhythmia analysis, medical imaging core lab services, the Opal V2R precision motion wearable sensor platform, and respiratory solutions including site-based and virtual spirometry. Underlying the product suite is a cloud-native trial enablement layer for screening, eligibility, source document management, and analytics. MedAvante also holds exclusive distribution rights to the eC-SSRS electronic Columbia Suicide Severity Rating Scale for self-reported suicidal ideation monitoring in CNS trials, and has launched Image Redact AI to automate the redaction of patient identifiers in imaging, video, and PDF artifacts.

MedAvante operates an enterprise sales model targeting pharma, biotech, and CRO buyers with quote-based, multi-year master agreements covering site-based, hybrid, and decentralized clinical trial deployments. In 2026, the company was acquired by Thermo Fisher Scientific as part of the broader acquisition of Clario Holdings Inc., which had integrated MedAvante's endpoint technology platform. The company's go-to-market combines direct enterprise engagement with content-led demand generation through its corporate website, scientific publications, industry conferences, and webinars aimed at clinical operations and biostatistics buyers.

Name

MedAvante

Website

https://medavante.com

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

101–250 employees

Short description

MedAvante is a clinical trial technology and services company providing technology-enabled signal detection and endpoint solutions — including eCOA, cardiac safety, imaging, motion, and respiratory — to pharmaceutical, biotech, and CRO sponsors across global trials.

Ownership category

akta.pro rank

Product category

Clinical Trial Endpoint Technology

NAICS

Other Scientific and Technical Consulting Services (541690), Medical Equipment and Supplies Manufacturing (3391)

SIC

Services-Prepackaged Software (7372), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

eCOA/ePRO/eDiary & Patient-Facing Data Collection (HLACAOAB)

akta.pro secondary industries

Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM), Clinical Trial Monitoring Support (On-site/Remote) (HLAGACAG), Site & Investigator Platforms (Site Payments, Feasibility, Activation) (HLACAOAJ)

Keywords

• Clinical trial endpoints
• Electronic clinical outcome assessment
• Cardiac safety solutions
• Medical imaging core lab
• Precision motion wearables

Headquarters

HQ city

Hackensack

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Distribution channels1 record

Marketing channels6 records

Core offering

MedAvante provides technology-enabled clinical trial endpoint solutions for pharmaceutical, biotechnology, and CRO sponsors. Its offerings span electronic clinical outcome assessments (eCOA), cardiac safety monitoring, medical imaging core lab services, precision motion wearables (Opal System), respiratory function testing, and cloud-native trial enablement software. These solutions are delivered across site-based, hybrid, and decentralized clinical trial models in over 100 countries.

Differentiator

Problem solved

Functional benefit

Products and services

• Cardiac Safety Solutions Cardiac safety and efficacy endpoint solutions including ECG monitoring, arrhythmia analysis, blood pressure data collection, and Phase I/TQT cardiac assessment for all trial phases, delivered to pharmaceutical, biotech, and CRO sponsors globally.
• eCOA (Electronic Clinical Outcome Assessment) Digital collection of patient-reported outcomes, clinician-reported outcomes, observer-reported outcomes, and performance outcomes for clinical trials, including neuroscience, early-phase oncology, rapid start assessment catalogs, science services, and rater training offerings.
• Medical Imaging Core Lab Services Comprehensive medical imaging core lab services including CT scans, endoscopy, MRIs and other modalities, backed by over 5,000 imaging studies and an experienced imaging science team with global key opinion leaders.
• Precision Motion / Opal System Wearable sensor technology for measuring objective digital endpoints of mobility, featuring the research-grade Opal V2R wearable sensor and supported by 750+ scientific publications reflecting its technical and clinical applications.
• Respiratory Solutions Pulmonary function testing including site-based spirometry, virtual home spirometry, cough and lung sounds assessment, diffusing capacity (DLCO), and oscillometry, generating reliable pulmonary data with low variability and high patient compliance.
• Trial Enablement Technology Cloud-native technologies and clinical trial software for participant screening, eligibility management, business intelligence analytics, and source document management, supporting site-based, hybrid, and decentralized clinical trials.
• Image Redact AI AI-powered solution that automatically redacts sensitive patient identifiers from videos, photos, and PDFs to support privacy and regulatory compliance in clinical trial imaging workflows.
• eC-SSRS (electronic Columbia Suicide Severity Rating Scale) Exclusive self-reported electronic Columbia Suicide Severity Rating Scale solution for monitoring suicidal ideation and behavior in clinical trials.

Quantifiable outcome

• 70% of FDA and EMA new drug approvals since 2015
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Veeva Systems: Veeva provides the Vault CTMS, EDC, and ePRO platform used across the life sciences industry. It is one of the closest software-direct comparables to MedAvante's eCOA and trial enablement technology stack.
• Signant Health: Signant Health (formed from CRF Health and Bracket) is a focused eCOA, patient engagement, and clinical outcome assessment provider. It is a direct competitor to MedAvante's eCOA franchise, particularly in CNS and rare disease trials.

Broad incumbents

• Parexel: Parexel is a global CRO with extensive clinical technology and decentralized trial offerings following its private-equity ownership. It competes with MedAvante on eCOA, cardiac safety, and integrated trial delivery.
• IQVIA: IQVIA is the largest global CRO and offers clinical trial technology, eCOA, and real-world evidence services. It competes head-to-head with MedAvante on endpoint solutions while bundling them with full-service CRO delivery to large pharma sponsors.
• Labcorp Drug Development (Fortrea): Fortrea (spun out from Labcorp) is a major global CRO with central laboratory, imaging, and eCOA capabilities. It is a broad incumbent that competes with MedAvante across multiple endpoint modalities as part of integrated CRO contracts.
• ICON plc: ICON is a top-3 global CRO with significant clinical technology and decentralized trial capabilities following its PRA Health Sciences acquisition. It directly competes with MedAvante for endpoint and eCOA work within full-service CRO engagements.
• Medpace: Medpace is a full-service CRO focused on small-to-mid biotech, with growing clinical technology capabilities. It competes with MedAvante for endpoint work, particularly from emerging biotech sponsors.
• Oracle Health Sciences (Clinical One / Inform): Oracle's Health Sciences unit (inheriting Phase Forward and Covance assets) offers EDC, CTMS, and eClinical platforms. It competes with MedAvante's trial enablement technology and is embedded in many large pharma technology stacks.

Emerging players

• Castor EDC: Castor is an emerging clinical trial data capture and eClinical platform competing in the same eCOA/EDC category as MedAvante's trial enablement offerings, particularly for smaller and academic-led studies.
• BioClin (now part of WCG) / WCG Clinical: WCG and its affiliates provide eCOA, rater training, and CNS clinical solutions (including the MedAvante-ProTrials heritage businesses). They overlap with MedAvante on rater-based outcome assessments and CNS trial enablement.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/medavante
• LinkedInlinkedin.com/company/medavante

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MedAvante